{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:06:07Z","timestamp":1784761567192,"version":"3.55.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A subset of triple negative breast cancer (TNBC) patients shows resistance to standard neoadjuvant chemotherapy (NAC), resulting in high relapse and mortality risk. This highlights the need for predictive biomarkers and alternative treatment strategies. Targeted molecular profiling was performed on post-NAC resection specimens from 138 TNBC patients, diagnosed across multiple centers between 2013 and 2022, all exhibiting extensive poor response, defined as &gt;50% residual tumor and the development of distant metastasis. Integrated immunohistochemistry and genomic analyses were conducted to identify potentially targetable alterations. Most post-NAC TNBCs (60%) were HER2-ultralow or HER2-low. Among 85 patients with successful DNA sequencing, 2640 variants were detected, with\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations being most frequent (94%). Mutation count ranged from 3 to 1668 per patient (median\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911). Several altered genes, including\n                    <jats:italic>ERBB2<\/jats:italic>\n                    ,\n                    <jats:italic>BRCA1\/2, PIK3CA, and RB1<\/jats:italic>\n                    , have been associated with favorable responses to targeted therapeutics in clinical trials. Moreover, 208 potential neo-peptide targets (median per patient\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093) were detected across recurrently mutated genes such as\n                    <jats:italic>ATM, CREBBP<\/jats:italic>\n                    ,\n                    <jats:italic>IRS2<\/jats:italic>\n                    ,\n                    <jats:italic>KEAP1, MSH6, NOTCH1, NOTCH2, POLD1, TP53<\/jats:italic>\n                    , and\n                    <jats:italic>TSC2<\/jats:italic>\n                    . Molecular profiling of residual disease in extensively poor responding TNBC post-NAC revealed multiple potentially targetable variant, supporting the use of next-generation sequencing to guide personalized strategies for these high-risk TNBC patients.\n                  <\/jats:p>","DOI":"10.1038\/s41523-026-00964-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:28:56Z","timestamp":1778624936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-4876","authenticated-orcid":false,"given":"Nadine S.","family":"van den Ende","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W. M.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien H. M.","family":"van Deurzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"964_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00428-022-03276-w","volume":"480","author":"A-V Laenkholm","year":"2022","unstructured":"Laenkholm, A.-V. et al. Incorporation of TILs in daily breast cancer care: how much evidence can we bear? Virchows Arch. 480, 147\u2013162 (2022).","journal-title":"Virchows Arch."},{"key":"964_CR2","doi-asserted-by":"crossref","unstructured":"Geurts, V. C. M. et al. Tumor-infiltrating lymphocytes in patients with stage I triple-negative breast cancer untreated with chemotherapy. JAMA Oncol. 10, 1077\u20131086 (2024).","DOI":"10.1001\/jamaoncol.2024.1917"},{"key":"964_CR3","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","volume":"331","author":"RA Leon-Ferre","year":"2024","unstructured":"Leon-Ferre, R. A. et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA 331, 1135\u20131144 (2024).","journal-title":"JAMA"},{"key":"964_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00607-1","volume":"10","author":"E Zaikova","year":"2024","unstructured":"Zaikova, E. et al. Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. npj Breast Cancer 10, 3 (2024).","journal-title":"npj Breast Cancer"},{"key":"964_CR5","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.24.00372","volume":"42","author":"M Kok","year":"2024","unstructured":"Kok, M. et al. Academic uphill battle to personalize treatment for patients with stage II\/III triple-negative breast Cancer. J. Clin. Oncol. 42, 3523\u20133529 (2024).","journal-title":"J. Clin. Oncol."},{"key":"964_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"964_CR7","doi-asserted-by":"crossref","unstructured":"van den Ende, N. S. et al. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int. J. Mol. Sci. 24, 2969 (2023).","DOI":"10.3390\/ijms24032969"},{"key":"964_CR8","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans, W. F. et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J. Clin. Oncol. 35, 1049\u20131060 (2017).","journal-title":"J. Clin. Oncol."},{"key":"964_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau, C. et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 23, 149\u2013160 (2022).","journal-title":"Lancet Oncol."},{"key":"964_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro, A. C., Lin, N. U. & Polyak, K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 9, 176\u2013198 (2019).","journal-title":"Cancer Discov."},{"key":"964_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer \u2014 expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"964_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1513421","volume":"15","author":"L Serrano Garc\u00eda","year":"2024","unstructured":"Serrano Garc\u00eda, L. et al. Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review. Front. Immunol. 15, 1513421 (2024).","journal-title":"Front. Immunol."},{"key":"964_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain, A., Barge, A. & Parris, C. N. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene 44, 193\u2013207 (2025).","journal-title":"Oncogene"},{"key":"964_CR14","doi-asserted-by":"publisher","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","volume":"42","author":"G Curigliano","year":"2024","unstructured":"Curigliano, G. et al. Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): primary results from DESTINY-Breast06 (DB-06). J. Clin. Oncol. 42, LBA1000\u2013LBA1000 (2024).","journal-title":"J. Clin. Oncol."},{"key":"964_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1158\/1078-0432.CCR-19-0285","volume":"26","author":"D Hammerl","year":"2020","unstructured":"Hammerl, D. et al. Clonality, antigen recognition, and suppression of CD8+ T cells differentially affect prognosis of breast cancer subtypes. Clin. Cancer Res. 26, 505\u2013517 (2020).","journal-title":"Clin. Cancer Res."},{"key":"964_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target. Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"964_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schr\u00f6rs, B., L\u00f6wer, M., T\u00fcreci, \u00d6 & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"964_CR18","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/biomedicines13092213","volume":"13","author":"PA Shatalov","year":"2025","unstructured":"Shatalov, P. A. et al. Neoantigen-driven immunotherapy in triple-negative breast cancer: emerging strategies and clinical potential. Biomedicines 13, 2213 (2025).","journal-title":"Biomedicines"},{"key":"964_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/ijo.2025.5749","volume":"66","author":"H Feng","year":"2025","unstructured":"Feng, H., Jin, Y. & Wu, B. Strategies for neoantigen screening and immunogenicity validation in cancer immunotherapy (Review). Int. J. Oncol. 66, 43 (2025).","journal-title":"Int. J. Oncol."},{"key":"964_CR20","doi-asserted-by":"crossref","unstructured":"Brito Baleeiro, R. et al. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer. J. Immunother. Cancer 11, e007336 (2023).","DOI":"10.1136\/jitc-2023-007336"},{"key":"964_CR21","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.it.2018.09.004","volume":"39","author":"D Hammerl","year":"2018","unstructured":"Hammerl, D., Rieder, D., Martens, J. W. M., Trajanoski, Z. & Debets, R. Adoptive T cell therapy: new avenues leading to safe targets and powerful allies. Trends Immunol. 39, 921\u2013936 (2018).","journal-title":"Trends Immunol."},{"key":"964_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cphg.93","volume":"103","author":"SM Harrison","year":"2019","unstructured":"Harrison, S. M., Biesecker, L. G. & Rehm, H. L. Overview of specifications to the ACMG\/AMP variant interpretation guidelines. Curr. Protoc. Hum. Genet 103, e93 (2019).","journal-title":"Curr. Protoc. Hum. Genet"},{"key":"964_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"964_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko, J. M. et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 4, 232\u2013245 (2014).","journal-title":"Cancer Discov."},{"key":"964_CR25","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia, A. et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N. Engl. J. Med. 391, 2110\u20132122 (2024).","journal-title":"N. Engl. J. Med."},{"key":"964_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"964_CR27","doi-asserted-by":"crossref","unstructured":"Li, Z., Han, Y., Wang, J. & Xu, B. Prognostic factors for triple-negative breast cancer with residual disease after neoadjuvant chemotherapy. J. Pers. Med. 13, 190 (2023).","DOI":"10.3390\/jpm13020190"},{"key":"964_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10020-021-00331-1","volume":"27","author":"A Qvick","year":"2021","unstructured":"Qvick, A. et al. Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer. Mol. Med. 27, 68 (2021).","journal-title":"Mol. Med."},{"key":"964_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41586-021-04278-5","volume":"601","author":"SJ Sammut","year":"2022","unstructured":"Sammut, S. J. et al. Multi-omic machine learning predictor of breast cancer therapy response. Nature 601, 623\u2013629 (2022).","journal-title":"Nature"},{"key":"964_CR30","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-16-2857","volume":"23","author":"CKY Ng","year":"2017","unstructured":"Ng, C. K. Y. et al. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas. Clin. Cancer Res. 23, 3859\u20133870 (2017).","journal-title":"Clin. Cancer Res"},{"key":"964_CR31","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1038\/s41588-019-0507-7","volume":"51","author":"L Angus","year":"2019","unstructured":"Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450\u20131458 (2019).","journal-title":"Nat. Genet."},{"key":"964_CR32","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1111\/cas.16208","volume":"115","author":"Q Yan","year":"2024","unstructured":"Yan, Q., Deng, Y. & Zhang, Q. A comprehensive overview of metaplastic breast cancer: Features and treatments. Cancer Sci. 115, 2506\u20132514 (2024).","journal-title":"Cancer Sci."},{"key":"964_CR33","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1016\/S0021-9258(17)47282-6","volume":"259","author":"KM Tewey","year":"1984","unstructured":"Tewey, K. M., Chen, G. L., Nelson, E. M. & Liu, L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259, 9182\u20139187 (1984).","journal-title":"J. Biol. Chem."},{"key":"964_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00674-y","volume":"10","author":"SP Myers","year":"2024","unstructured":"Myers, S. P. et al. Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers. npj Breast Cancer 10, 63 (2024).","journal-title":"npj Breast Cancer"},{"key":"964_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108366","volume":"33","author":"MR Wilson","year":"2020","unstructured":"Wilson, M. R. et al. ARID1A mutations promote P300-dependent endometrial invasion through super-enhancer hyperacetylation. Cell Rep. 33, 108366 (2020).","journal-title":"Cell Rep."},{"key":"964_CR36","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"HP Zhang","year":"2024","unstructured":"Zhang, H. P. et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer 31, 539\u2013551 (2024).","journal-title":"Breast Cancer"},{"key":"964_CR37","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.27877","volume":"12","author":"TA O\u2019Meara","year":"2021","unstructured":"O\u2019Meara, T. A. & Tolaney, S. M. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget 12, 394\u2013400 (2021).","journal-title":"Oncotarget"},{"key":"964_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/biomedinformatics5010009","volume":"5","author":"H Bendani","year":"2025","unstructured":"Bendani, H., Boumajdi, N., Belyamani, L. & Ibrahimi, A. A decision-aid model for predicting triple-negative breast cancer ICI response based on tumor mutation burden. BioMedInformatics 5, 9 (2025).","journal-title":"BioMedInformatics"},{"key":"964_CR39","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/2159-8290.CD-24-0168","volume":"14","author":"D Kortleve","year":"2024","unstructured":"Kortleve, D. et al. TCR-engineered T cells directed against ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer. Cancer Discov. 14, 2450\u20132470 (2024).","journal-title":"Cancer Discov."},{"key":"964_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101200","volume":"67","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy in endocrine therapy-resistant breast cancer. Neoplasia 67, 101200 (2025).","journal-title":"Neoplasia"},{"key":"964_CR41","doi-asserted-by":"publisher","first-page":"e0264138","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury, C. A. et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE 17, e0264138 (2022).","journal-title":"PLoS ONE"},{"key":"964_CR42","first-page":"19","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie, M. et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 29, 19\u201324 (2007).","journal-title":"Cell Oncol."},{"key":"964_CR43","unstructured":"NABON\/NIV. Dutch Clinical Guideline of Breast Cancer: Kennisinstituut van de Federatie van Medische Specialisten; [Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/pathologie.html."},{"key":"964_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-018-3477-4","volume":"11","author":"AA Hashmi","year":"2018","unstructured":"Hashmi, A. A. et al. Cytokeratin 5\/6 and cytokeratin 8\/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. BMC Res. Notes 11, 372 (2018).","journal-title":"BMC Res. Notes"},{"key":"964_CR45","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch. Pathol. Lab Med. 142, 1364\u20131382 (2018).","journal-title":"Arch. Pathol. Lab Med"},{"key":"964_CR46","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen, T. O. et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst. 113, 808\u2013819 (2021).","journal-title":"J. Natl. Cancer Inst."},{"key":"964_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259\u2013271 (2015).","journal-title":"Ann. Oncol."},{"key":"964_CR48","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.annonc.2021.07.007","volume":"32","author":"S Loi","year":"2021","unstructured":"Loi, S. et al. The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann. Oncol. 32, 1236\u20131244 (2021).","journal-title":"Ann. Oncol."},{"key":"964_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"964_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1114-x","volume":"17","author":"S Canisius","year":"2016","unstructured":"Canisius, S., Martens, J. W. M. & Wessels, L. F. A. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 17, 261 (2016).","journal-title":"Genome Biol."},{"key":"964_CR51","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"964_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: a Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"964_CR53","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"964_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12910","volume":"7","author":"M Smid","year":"2016","unstructured":"Smid, M. et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat. Commun. 7, 12910 (2016).","journal-title":"Nat. Commun."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00964-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00964-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00964-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:53:39Z","timestamp":1784760819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-00964-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-00964-7","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roche delivered the materials for DNA isolation and sequencing; however, this did not have any influence on the substantive matters within this article. C.H.M. van Deurzen has received research funding from AstraZeneca, which was unrelated to this project. R. Debets received research support from MSD and Bayer, personal fees from Bluebird Bio, Genticel, other support from Pan Cancer T, which was unrelated to the submitted work (all paid to the Erasmus MC Cancer Institute), as well as European patent application nos. 21152822.9, 24192717.7, and 25163944.9 (pending to Erasmus MC). J.W.M. Martens received research funding from Menarini, Tzu genomics, MSD, and Pfizer, and a consultancy fee from Novartis; these were all unrelated to this project. All the other authors declare no potential competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"94"}}